2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06C.05 Impact of TP53 Mutation in Advanced NSCLC in LATAM

Pdf Summary

The study titled "Impact of TP53 Mutation on Advanced NSCLC in LATAM," conducted by Runciman et al., assesses the impact of TP53 mutations on non-small cell lung cancer (NSCLC) in Latin American populations, which are often underrepresented in international research. The study analyzed data from 462 Latin American patients with advanced lung cancer treated at Clinica Aliada in Peru and Instituto Nacional de Cancerología in Mexico, covering the period from January 2015 to December 2022. After excluding patients lost to follow-up or without complete genomic sequencing data, 356 patients were included in the analysis.<br /><br />The study found that TP53 mutations were present in 41.7% of patients, with a higher prevalence in males and a mean age of 57.7 years. No significant difference was observed in the prevalence of these mutations based on smoking status. The presence of the TP53 mutation was associated with a significantly poorer overall survival (OS) compared to those without the mutation, with median survival times of 21.5 months for patients with the mutation versus 46.5 months for those without. Specifically, patients with concurrent EGFR or KRAS mutations and TP53 mutations exhibited particularly poor survival outcomes. However, there was no notable difference in progression-free survival (PFS) based on TP53 mutation status.<br /><br />This study provides valuable insights into the prevalence and impact of TP53 mutations in the Latin American NSCLC patient population, underscoring the mutation's detrimental effect on overall survival, especially in conjunction with other driver mutations like EGFR and KRAS. This research fills a significant gap by focusing on a demographic often overlooked in global studies, offering critical data for tailored treatment strategies in Latin American populations.

Asset Subtitle

Thanya Runciman

Meta Tag

Speaker Thanya Runciman

Topic Pathology and Biomarkers

Keywords

TP53 mutation

NSCLC

Latin America

lung cancer

Runciman et al.

overall survival

EGFR mutation

KRAS mutation

genomic sequencing

Clinica Aliada